01 / Innovation
Curetanics’ mission is to contribute to the fight against cancer across prevention, therapy support and post-treatment care. CCRM is in operational use. The workflow starts with individual analysis, because cancers differ between people, vary within a tumor and can evolve under treatment.
Curetanics’ innovation thesis
Marcus Peruscha
The fight against cancer · A scientific mission
Contributing to the fight against cancer starts with its biology: deregulated growth, resistance to cell death, altered metabolism and interactions with surrounding tissue. Cancer is a diverse group of diseases, not one fixed target. These behaviors make biological context and timing central to the research questions Curetanics aims to investigate.
Genetically distinct subclones and different cell states can coexist within a tumor. Multiregion sequencing in kidney cancer showed why one specimen may miss genetic diversity. Research must therefore ask which cells and tissue a finding represents; a single molecular observation may not describe the whole disease.
Research in EGFR-mutant lung cancer identified resistance arising from pre-existing resistant clones or from initially drug-tolerant cells. Treatment can change the composition of a tumor population. A contextual approach must therefore ask how prior therapy, sampling time and emerging resistance change the relevance of a mechanistic hypothesis.
Cancer behavior also depends on immune cells, supporting tissue, blood supply and local signals. Some tumors evade immune elimination or shape conditions that weaken antitumor responses. The scientific question is which interaction matters in a defined setting; a general claim of “boosting immunity” cannot capture these opposing effects.
Metastasis involves invasion, transport and growth in a distant tissue; many disseminating cells do not complete these steps, and some can remain dormant. A finding in a primary tumor cannot automatically describe another organ or disease phase. Research must preserve site, stage and time rather than assume uniform behavior.
Curetanics’ innovation thesis responds to this complexity by connecting evidence with context, exposure, timing and interaction constraints. The mission is to support precise, testable research questions in the fight against cancer. These mechanisms define questions for research; they do not establish efficacy for a compound or model. Clinical decisions remain with the treating oncology team.
Research context
Change the research phase to see why a molecular finding cannot be transferred into an individual conclusion without context. This is a conceptual example, not a CCRM simulation.
Review the relevant available clinical, molecular, laboratory, medication and time-related findings.
Preserve sources, units, timing, context and missing information.
Connect the individual question to sourced compound, target and pathway evidence.
Apply exposure, interaction and uncertainty constraints to the specified question.
Present traceable findings, limits and unresolved questions for responsible review.
No named compound, patient profile, risk score or clinical recommendation is generated.
Compounds can affect several molecular targets, and cellular phenotypes emerge from interacting processes. Network medicine supplies an established framework for organizing these relationships. Curetanics brings that systems view into an operational workflow focused on bioactive compounds and cancer-related questions. Individual analysis defines the context before evidence is mapped. The practical innovation concerns the integration of established knowledge, the constraints applied and the traceability of the resulting hypotheses. Claims of added value or superiority must remain tied to their specific evaluation.
A molecular association has a tissue, cell-state and measurement context. GTEx demonstrates that genetic regulation of gene expression varies across human tissues; it does not identify an individual cancer therapy. After individual analysis, the CCRM workflow preserves tissue relevance, timing, treatment exposure and uncertainty instead of treating a pathway annotation as universally applicable. Repeated observations help represent a changing biological situation; the relevance of each feature remains specific to the intended research question.
The Connectivity Map connects compounds and genetic perturbations through measured gene-expression signatures. Such resources make it possible to investigate related or opposing responses in defined experimental systems. Where relevant perturbation evidence is available, the CCRM workflow interprets it against the individual profile alongside target and pathway knowledge. Signature similarity or reversal is a starting point for experiments, not proof of anticancer activity. Cell line, concentration, exposure duration and the measured endpoint remain attached to each inference.
Mechanistic relevance depends on whether an active substance reaches the relevant biological compartment. Total concentration, intracellular unbound exposure and an ingested amount are different quantities. Interaction evidence adds another constraint: supplements can alter cancer-drug metabolism or transport, while information about many combinations remains limited. CCRM includes these constraints when contextualizing a hypothesis after individual analysis. Exposure assumptions, compound and formulation identity, and unresolved safety questions remain explicit.
An informative output separates measured observations, imported annotations, model assumptions and inferred relationships. MIRIAM provides established principles for connecting model entities with biological meaning and provenance. The integrated workflow preserves source versions, transformations, parameter choices and competing explanations so a reviewer can inspect why a hypothesis was produced. AI may assist retrieval, mapping or pattern discovery, but a fluent explanation does not establish causality. The contribution is a traceable reasoning process whose failures can also be investigated.
Prevention, support during therapy and post-treatment care involve different populations, time horizons and outcomes. All three CCRM pathways begin with individual analysis and profile structuring. The question, admissible evidence and interaction constraints then change with the setting. A pathway finding relevant to treatment stress cannot automatically support a prevention claim or a reduction in recurrence. Clinical predictions and applications require evaluation for the intended population and use, with transparent reporting of limitations.
The cited research establishes the scientific foundations and their limits. It does not establish Curetanics’ novelty, implementation, accuracy or clinical benefit. Reference titles remain in their original language.